[Case of brexu-cel at first relapse in an elderly patient].

[INTRODUCTION] Relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) represents a complex clinical scenario, and the advent of immunotherapy has radically changed the therapeutic options available for these patients. The introduction of CAR-T cell therapy for patients over 25 years old offers a new treatment opportunity, with high remission rates and durable responses.

[CLINICAL CASE] A 67-year-old female patient with multiple comorbidities was diagnosed with Philadelphia-negative B-ALL and treated with induction therapy according to the GIMEMA LAL1913 protocol plus rituximab with dose reductions due to age, achieving a complete MRD-negative complete remission (CR). During the sixth month of maintenance therapy, a relapse was diagnosed. The patient was then referred for brexu-cel treatment, following bridging therapy with inotuzumab which led to the achievement of MRD-positive remission. Brexu-cel therapy was complicated by grade 1 CRS, grade 1 ICANS, and an episode of atrial fibrillation, but ultimately led to a complete MRD-negative CR. The patient remains in complete MRD-negative remission over one year after therapy, without the need for further treatment.

[CONCLUSION] Brexu-cel represents an effective treatment option for patients with R/R B-ALL. In patients with comorbidities and significant transplant-related risks, prolonged remissions can be maintained even without additional consolidation therapies. Optimization of bridging therapy, monitoring, and toxicity management is essential.